文献速递青光眼

口服美金刚治疗青光眼:两项随机安慰剂对照3期研究的设计与结果

Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.
PubMed 文献 · Ophthalmology · 2018-08-03

两项设计相同的随机双盲安慰剂对照多中心48个月3期研究,共纳入2298例有进展风险的开角型青光眼患者,比较口服美金刚10mg、20mg与安慰剂的疗效与安全性。结果显示,与安慰剂相比,美金刚未显著延缓青光眼性进展,最常见导致停药的不良事件为头晕、头痛、疲劳和恶心。

要点

  • 口服美金刚10mg或20mg每日治疗48个月未显著延缓开角型青光眼进展。
  • 基于标准自动视野计(SAP)的汇总风险降低比(95%CI)在10mg组为-0.13(-0.40, 0.09),20mg组为-0.17(-0.46, 0.07)。
  • 频域倍增技术(FDT)和立体视盘照相结果与SAP相似,常见停药不良事件为头晕、头痛、疲劳和恶心。

核心结论

  • 在当时的可用技术条件下,每日口服美金刚48个月未能证实可预防该患者人群的青光眼性进展。

研究设计与样本

  • 两项设计相同的随机、双盲、安慰剂对照、平行组、多中心48个月研究,间隔1年启动,于2006年完成。
  • 共纳入2298例双侧开角型青光眼患者,按3:2:2随机接受美金刚20mg、10mg或安慰剂每日片剂。

主要发现

  • 各治疗组完成研究的患者比例相似(80%-83%)。
  • 与安慰剂相比,美金刚10mg或20mg每日治疗48个月在单项研究和汇总分析中均未显著延缓青光眼性进展。
  • 基于SAP的汇总风险降低比(95%CI)在美金刚10mg组为-0.13(-0.40, 0.09),20mg组为-0.17(-0.46, 0.07)。
  • 基于FDT和立体视盘照相的进展结果与SAP相似。
  • 导致治疗中断的最常见不良事件为头晕、头痛、疲劳和恶心。

临床怎么用

  • 现有证据不支持口服美金刚用于开角型青光眼进展的神经保护治疗。

局限性

  • 研究设计与结果基于研究开展时(至2006年)可用的技术。
  • 方案曾进行修订,包括第一项研究延长1年以及第二项研究更换主要终点和分析方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effectiveness and safety of oral memantine as a potential neuroprotective agent in open-angle glaucoma (OAG) at risk for progression. DESIGN: Two randomized, double-masked, placebo-controlled, parallel-group, multicenter, 48-month studies identically designed, initiated 1 year apart, and completed in 2006. Protocol amendments included a 1-year extension (first study) and change in primary endpoint and analysis (second study). PARTICIPANTS: Patients (2298 total) with bilateral OAG; glaucomatous optic disc damage and visual field loss in 1 eye; glaucomatous optic disc damage and/or visual field loss in the contralateral eye (at screening), topically treated or untreated intraocular pressure (IOP) of 21 mmHg or less (at baseline); and at risk of glaucomatous progression (per prespecified criteria). METHODS: Patients were randomized 3:2:2 to receive memantine 20 mg, memantine 10 mg, or placebo tablets daily. Glaucomatous progression was assessed in the intent-to-treat population by full-threshold standard automated perimetry (SAP), frequency doubling technology (FDT), and stereoscopic optic disc photographs, standardized by quality control assessment at centralized reading centers. Safety evaluations included adverse events (AEs), best-corrected visual acuity, biomicroscopy, IOP, and ophthalmoscopy. Efficacy data from each study were analyzed per protocol. Pooled analyses of efficacy and safety data were also performed. MAIN OUTCOME MEASURES: The predefined primary efficacy measure was glaucomatous visual field progression, as measured by SAP. Additional efficacy measures included glaucomatous progression of visual field (FDT) and optic nerve damage (stereoscopic optic disc photographs). RESULTS: The proportion of patients who completed the studies was similar among groups (80%-83%). Compared with placebo, daily treatment with memantine 10 mg or 20 mg for 48 months did not delay glaucomatous progression significantly in the individual studies and pooled analyses. The pooled risk reduction ratio (95% confidence interval) assessed by SAP was -0.13 (-0.40, 0.09) and -0.17 (-0.46, 0.07) for memantine 10 mg and 20 mg, respectively. Results were similar per FDT and stereoscopic optic disc photographs. The most common AEs leading to treatment discontinuations were dizziness, headache, fatigue, and nausea. CONCLUSIONS: With technologies available when the studies were conducted, daily treatment with memantine over 48 months was not shown to prevent glaucomatous progression in this patient population.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Weinreb RN, Liebmann JM, Cioffi GA, et al. Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies. Ophthalmology. 2018. PMID: 30082073. doi:10.1016/j.ophtha.2018.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。